卡巴他赛和水飞蓟宾共包封阳离子脂质体用于 CD44 靶向递药:基于纳米医学的联合化疗治疗前列腺癌的新见解。
Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate cancer.
机构信息
Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research (NIPER), Hyderabad 500037, India.
Central Research Institute of Unani Medicine (CRIUM), Hyderabad 500 038, India.
出版信息
Biomed Pharmacother. 2019 Feb;110:803-817. doi: 10.1016/j.biopha.2018.11.145. Epub 2018 Dec 13.
Cancer stem cells (CSCs) are the promising targets for cancer chemotherapy that cannot be eliminated by conventional chemotherapy. In this study cationic liposomes of cabazitaxel (CBX) and silibinin (SIL) were prepared with an aim to kill cancer cells and CSCs for prostate cancer. CBX act as cancer cell inhibitor and SIL as CSC inhibitor. Hyaluronic acid (HA), an endogenous anionic polysaccharide was coated on cationic liposomes for targeting CD44 receptors over expressed on CSCs. Liposomes were prepared by ethanol injection method with particle size below 100 nm and entrapment efficiency of more than 90% at 10% w/w drug loading. Liposomes were characterized by dynamic light scattering, transmission electron microscopy, H nuclear magnetic resonance and scanning electron microscopy-energy dispersive x-ray spectroscopy. Liposomes were evaluated for their anticancer action in androgen independent human prostate cancer cell lines (PC-3 and DU-145). HA coated liposomes showed potential cytotoxicity over other groups with low IC, significantly inhibited cell migration and induced apoptosis. Synergistic cytotoxic effect was also observed with HA coated liposomes that resulted in colony formation inhibition and G2/M phase arrest. Proficient cytotoxicity against CD44 cells (14.87 ± 0.41% in PC-3 and 33.95 ± 0.68% in DU-145 cells) indicated the efficiency of HA coated liposomes towards CSC targeting. Hence, the outcome of this combinational therapy with CD44 targeting indicates the suitability of HA coated CBX and SIL co-loaded liposomes as a potential approach for eradicating prostate cancer and herein might provide a insight for future studies.
癌症干细胞 (CSCs) 是癌症化疗的有前途的靶点,常规化疗无法消除它们。在这项研究中,制备了卡巴他赛 (CBX) 和水飞蓟宾 (SIL) 的阳离子脂质体,目的是杀死前列腺癌细胞和 CSCs。CBX 作为癌细胞抑制剂,SIL 作为 CSC 抑制剂。透明质酸 (HA) 是一种内源性阴离子多糖,被涂覆在阳离子脂质体上,以靶向在 CSCs 上过表达的 CD44 受体。脂质体通过乙醇注入法制备,粒径小于 100nm,载药 10%w/w 时包封效率超过 90%。通过动态光散射、透射电子显微镜、H 核磁共振和扫描电子显微镜-能谱对脂质体进行了表征。脂质体的抗癌作用在雄激素非依赖性人前列腺癌细胞系 (PC-3 和 DU-145) 中进行了评价。HA 涂层脂质体显示出比其他组更大的潜在细胞毒性,具有较低的 IC,显著抑制细胞迁移并诱导细胞凋亡。HA 涂层脂质体还观察到协同细胞毒性作用,导致集落形成抑制和 G2/M 期阻滞。对 CD44 细胞的高效细胞毒性(PC-3 细胞中的 14.87±0.41%和 DU-145 细胞中的 33.95±0.68%)表明 HA 涂层脂质体对 CSC 靶向的效率。因此,这种联合治疗与 CD44 靶向的结果表明,HA 涂层 CBX 和 SIL 共载脂质体作为根除前列腺癌的潜在方法是合适的,这可能为未来的研究提供一些启示。